Patent 7960376 was granted and assigned to Cara Therapeutics on June, 2011 by the United States Patent and Trademark Office.
The present invention provides benzo-fused heterocyclic compounds having the structure of formula I, as well as prodrugs, stereoisomers, racemates, salts, hydrates, solvates, acid salt hydrates and isomorphic crystalline forms thereof.